The initiation of a Phase 2/3 trial for KPL-387 in recurrent pericarditis suggests potential future revenue streams and aligns with Kiniksa's strategic focus on cardiovascular diseases. The discontinuation of abiprubart in Sjögren's Disease indicates a shift in resource allocation, which could positively impact the company's focus and efficiency.